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Melanoma Is Up:  
Are We Up to This challenge?
Kachiu C. Lee1 and Martin A. Weinstock1
Linos and colleagues provide important evidence that the increasing incidence 
of melanoma is not solely from  increases in thin melanomas discovered by more 
intensive screening.  This underscores the inadequacy of primary prevention to 
date, and the importance of early detection for reducing mortality in the near 
future.   The US Preventive Services Task force finds insufficient evidence to rec-
ommend for or against skin self-examination and clinician skin examination. 
Neither is commonly practiced now, but both are required for effective early 
detection.  Evidence regarding benefits, harms, and costs of melanoma screening 
will help in securing widespread endorsement of these activities.
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Melanoma incidence has been increas-
ing in the United States since population-
based measures became available more 
than 70 years ago. As long as the mor-
tality from melanoma also continued to 
rise, there was relatively little controversy 
about whether this neoplasm was really 
increasing in frequency. However, for the 
past decade or two, melanoma mortality 
has leveled off, giving rise to a debate 
about whether the continuing increase in 
incidence is due to a real increase in the 
frequency of the disease or whether it is 
an artifact of increasing public and med-
ical attention to skin cancer, with asso-
ciated increased rates of skin biopsies 
leading to increased diagnosis of thin, 
relatively indolent lesions or lesions that 
are diagnosed as melanoma but are not 
actually malignant (Edman and Klaus, 
2000; Welch et al., 2005).
Linos and colleagues (2009, this 
issue) step into the fray with their analy-
sis of the population-based Surveillance, 
Epidemiology, and End Results (SEER) 
data, which reveal an increase in inci-
dence of all major histologic subtypes 
and thickness groups of melanoma, 
including the thickest melanomas, which 
have the worst prognosis. The increases 
are reported to occur across the spec-
trum of socioeconomic status, including 
individuals with the poorest melanoma 
prognosis (Eide et al., 2009) and the 
poorest access to screening. With this 
analysis. Linos et al. have advanced the 
debate, but they have not ended it.
No longer can it be credibly claimed 
that the increase in melanoma incidence 
can be attributed solely to increases 
in the detection of thin melanomas. 
Although the number of melanomas 
with unknown tumor thickness in the 
SEER database was higher than desired, 
the authors conducted reasonable 
sensitivity analyses to suggest it is not 
responsible for the persistent increase 
in the disease across thickness groups. 
Fluctuations in the completeness of mel-
anoma registration are always a concern 
in database studies. However, perhaps 
the most serious concern is the apparent 
discrepancy between the increasing inci-
dence of thick as well as thin melano-
mas and stable mortality rates. Marginal 
therapeutic advances have been made 
in recent decades, but it remains undoc-
umented whether they are of sufficient 
magnitude to account for this observed 
discrepancy. Alternatively, misdiagnosis 
of benign lesions as melanoma may be 
more common, as may the detection 
of relatively indolent thick melanomas. 
We must consider the possibility of a 
shift in the distribution of melanoma 
types (we do not refer here to classic 
histologic types) to melanomas that are 
less aggressive at a given thickness than 
those occurring a decade ago. Perhaps 
the lag between diagnosis of a thick 
melanoma and death from that mela-
noma is relevant.
Although the debate about trends 
in melanoma is not over, the evidence 
is now substantially stronger that the 
increase in incidence is not merely an 
artifact of better detection practices but 
is due at least in part to an actual rise 
in the frequency of real disease. Recent 
research has also provided more insight 
into the impact of early detection prac-
tices on incidence and mortality, with 
the publication of the experience of 
employees at the Lawrence Livermore 
National Laboratories (Schneider et 
al., 2008). The group was subjected to 
increased awareness programs and ulti-
mately intensive screening, consisting of 
education about skin self-examination 
as well as clinical melanoma screening 
examinations. Among the participants 
there were progressively more diagnoses 
of in situ melanoma during this period 
but progressively fewer thick invasive 
melanomas were detected (see Figure 1). 
This adds to earlier evidence that inter-
vention to promote thorough skin self-
examination (TSSE) is associated with 
more skin surgery as an apparently tran-
sient consequence of regular TSSE per-
formance (Weinstock et al., 2007), but 
that lower melanoma mortality may be a 
result (Berwick et al., 1996).
Decreasing mortality is a key goal of 
prevention programs. Melanoma is pro-
jected to have killed 8,420 Americans in 
2008, and a similar number of deaths are 
expected in 2009. Primary prevention 
through reduced UVR exposure may 
ultimately reduce the number, but the 
lag time between exposure and death 
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screening for skin cancer and concluded, 
“There is insufficient evidence to assess 
the balance of benefits and harms of 
whole-body skin examination by a clini-
cian or patient skin self-examination for 
the early detection of skin cancer” (US 
Preventive Services Task Force, 2009). 
But in the same document, the USPSTF 
noted that “clinicians should remain alert 
for skin lesions with malignant features.” 
This apparent inconsistency illustrates a 
difficulty in adhering to their own criteria 
when evaluating clinical practices such 
as skin cancer screening (Weinstock, 
2000). However, recent developments 
may address this difficulty.
As a response to the perceived insuf-
ficient guidance for clinicians regarding 
many practices, even in the absence of 
evidence-based guidance, the USPSTF 
has identified a series of domains that it 
will take into account to provide guid-
ance to clinicians when the relevant evi-
dence is insufficient to meet its criteria 
for endorsing a recommendation (Petitti 
et al., 2009). These include (i) the poten-
tial preventable burden, (ii) the poten-
tial harms, (iii) costs, and (iv) current 
practice. In setting forth these domains, 
the USPSTF recognizes that the level 
of evidence that may be appropriate to 
persuade a clinician to recommend an 
invasive procedure, perhaps with some 
risk of death or severe morbidity, must be 
more stringent than the level of evidence 
appropriate for a procedure such as skin 
self-examination. Indeed, the USPSTF 
recognizes that some procedures, per-
haps including skin cancer screening, 
may never have sufficiently rigorous evi-
dence to support a recommendation by 
their criteria, so clinically informed rea-
soning based on available evidence of 
potential benefits and harms, as well as 
costs, will be key.
Because of the high costs of conduct-
ing a randomized controlled trial, no 
such study has been conducted to docu-
ment the relationship between screening 
and mortality. The Queensland, Australia, 
Melanoma Screening Trial came close to 
this goal; the investigators randomized 
9 of 18 communities to receive a mela-
noma screening intervention. Physicians 
in the intervention communities received 
training and support; residents of these 
communities received educational 
materials, as well as free screenings 
Skin is not thoroughly scrutinized by 
patients or their physicians for several 
reasons. Many patients lack the knowl-
edge, skills, and confidence to examine 
the skin for cancer or to distinguish sus-
picious from benign lesions; others are 
simply not motivated to do so, perhaps 
in part because of a lack of interest on 
the part of their health-care providers. 
Patients without partners or TSSE aids 
such as handheld or wall mirrors are also 
less likely to conduct TSSE, as are those 
whose physicians have not recommend-
ed this practice (Martin et al., 2007). On 
the physician side, PCPs often cite lack 
of time as the most significant barrier to 
performing FBSE. Poor reimbursement 
and competing patient comorbidities 
may pose additional hindrances, as may 
a lack of sufficient knowledge and skills. 
Physicians who doubt the effectiveness 
of FBSE and who lack confidence in 
their ability to detect lesions of concern 
are less likely to examine a patient’s skin 
(Geller et al., 2004).
Finally, insufficient evidence is cited 
as a critical impediment to conducting 
FBSE and even to recommending TSSE. 
The US Preventive Services Task Force 
(USPSTF) acts as an authoritative body 
in providing evidence-based recommen-
dations to clinicians regarding the effec-
tiveness of various prevention-related 
strategies and procedures, particularly in 
primary care. Earlier this year, the agency 
reevaluated their recommendations on 
from disease is typically long, and public 
health efforts have not proven effective 
at markedly reducing the population’s 
exposure. Indeed, sunburns are on the 
increase (Centers for Disease Control 
and Prevention, 2007), as well as inci-
dence of melanoma of all thicknesses. 
If the goal is to cut melanoma deaths at 
least by half in the next decade despite 
the trends noted by Linos et al. (2009), 
primary prevention by reducing individu-
als’ exposure to UVR will not accomplish 
this. Improved early detection might.
Early, curable melanoma is almost 
always asymptomatic but visible on the 
surface of the skin. To detect it, some-
one needs to look at the skin and see the 
lesion (Weinstock, 2000). Unfortunately, 
early detection practices for melanoma 
are not widely established. In a national 
survey of primary care providers (PCPs), 
only 32% reported routinely performing 
full-body skin examinations (FBSEs) on 
average-risk patients, and only 59% of 
physicians conducted FBSEs on patients 
at high risk for melanoma (Geller et 
al., 2004). National patient popula-
tion surveys have reported much lower 
screening rates, ranging from 16 to 21% 
(Oliveria et al., 2001; Santmyire et al., 
2001). TSSE is reported by less than 20% 
of the population, although some indi-
viduals may examine focused portions 
of their body (Weinstock et al., 1999, 
2007). Thus, most Americans undergo 
no systematic skin surveillance.
Figure 1. crude incidence of melanoma at the Lawrence Livermore national Laboratory (LLnL). The 
pre-awareness period (1969–1975) is the interval before widespread awareness of the high incidence 
rates of melanoma at LLNL. The early awareness period (1976–1984) involved increased awareness of 
the high incidence rates prior to the institution of a formal screening program. During the screening 
period (1984–1996), a screening and education program was in place (Schneider et al., 2008).
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by physicians. The prevalence of FBSE 
increased by approximately 20% over 
baseline, with self-screening by elderly 
men and women comprising the largest 
increase (Aitken et al., 2006b). The spec-
ificity of an FBSE was 86%, comparable 
to that of other routine screening pro-
cedures, for example, mammography 
(Aitken et al., 2006a). Unfortunately, the 
Queensland study could not be extended 
to the remainder of the 44 communities 
required for adequate power because of 
a lack of governmental funding, and the 
investigators could not adequately mea-
sure the effect of their intervention on 
melanoma mortality.
While the medical community 
optimistically waits for a large-scale ran-
domized study on screening to provide 
the strongest evidence, a key research 
focus must be to augment available 
evidence in the domains identified by 
the USPSTF, including potential harms 
and costs. Melanoma is generally vis-
ible on the skin at a curable phase in 
its evolution, when cure consists of a 
simple office procedure. Yet for most 
people, periodic, systematic skin surveil-
lance is not practiced—not by a clini-
cian, the patient, or the patient’s family. 
The absence of physician recommenda-
tion to perform skin exams is an impor-
tant factor. The recent broadening of the 
USPSTF’s view of relevant evidence for 
issues such as this offers a challenge to 
the research community and an oppor-
tunity to improve public health: are we 
up to the challenge of cutting melanoma 
mortality in half by providing adequate 
scientific support for broad implementa-
tion of effective early detection?
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Perp and Pemphigus: A Disease  
of Desmosome Destabilization
Meryem Bektas1 and David S. Rubenstein1,2
In this issue, Nguyen et al. demonstrate a role for Perp in desmosome 
assembly and trafficking and pemphigus IgG–mediated acantholysis, providing 
further insights into the complexity of desmosome structure and regulation.
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Desmosomes are multiprotein,  
polymeric cell–cell adhesion complexes
The desmosome intercellular adhe-
sive interface is formed by the extra-
cellular domains of desmogleins and 
desmocollins, single-pass transmem-
brane proteins belonging to the cad-
herin family of cell adhesion proteins. 
Other known desmosome compo-
nents include plakophilins, desmo-
plakins, and the catenin plakoglobin. 
The cytoplasmic tail of desmoglein 
binds to plakoglobin, which in turn 
binds to desmoplakin. Plakophilins 
bind to desmoplakins, plakoglobin, 
desmogleins, and desmocollins, and 
